What this means
This is a planned study that has not started enrolling people yet, so no results exist. It will not tell us anything about aging effects until it runs and reports.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 35 and over
- Where
- 2 sites, including Colorado, Texas
The science
- Registered title
- Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV
- Trial ID
- NCT07871552 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Epigenetic Aging
- What is tested
- Switch from an ART regimen containing lamivudine (3TC) or emtricitabine (FTC) + tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) to DOR/ISL, Switch from an nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL, Continue SoC ART
- Sponsor
- The University of Texas Health Science Center, Houston
- Ages
- 35 Years to no maximum
- Dates
- First posted Oct 13, 2026 · updated Oct 13, 2026
Registry summary
The purpose of this study is to quantify biologic aging (using validated epigenetic clocks) as downstream indicators of Long Interspersed Nuclear Element-1 (LINE-1) retrotransposon activity before and after switch to doravirine (DOR)/Islatravir (ISL) , to estimate whether effects of DOR/ISL on biologic aging vary by entry antiretroviral therapy (ART) regimen, and relative to continued standard of care (SoC) ART and to obtain the tolerability (adverse event profile) associated with switch to DOR/ISL relative to continued SoC ART
Sites (2)
- University of Colorado Anschutz Medical Center, Aurora, Colorado, United States
- The University of Texas Health Science Center at Houston, Houston, Texas, United States